["--- Page 1 ---\n2.3.4\nIn Vivo Assessment of Tissue\nCompatibility\nJAMES M. ANDERSON1, FREDERICK J. SCHOEN2, NICHOLAS P. ZIATS1\n1Department of Pathology, Case Western Reserve University, Cleveland, OH, United States\n2Pathology and Health Sciences and Technology (HST), Harvard Medical School, Department of\nPathology, Brigham and Women’s Hospital, Boston, MA, United States\nIntroduction Extensive efforts have been made by government regula-\ntory agencies, e.g., the US Food and Drug Administration", "Introduction Extensive efforts have been made by government regula-\ntory agencies, e.g., the US Food and Drug Administration\nThe goal of in vivo assessment of tissue compatibility of a (FDA), and standards organizations, e.g., ASTM Interna-\nbiomaterial, prosthesis, or medical device is to determine the tional (ASTM International, 2018 Annual Book of ASTM\nbiocompatibility (as a key component of safety) of the bio- Standards, Volume 13.01), the International Organization\nmaterial, prosthesis, or medical device in a biological envi- for Standardization (ISO), and US Pharmacopeia (USP),", "material, prosthesis, or medical device in a biological envi- for Standardization (ISO), and US Pharmacopeia (USP),\nronment. Indeed, biocompatibility is a critical element in to provide procedures, protocols, guidelines, and standards\nthe performance of an implanted medical device, and many that may be used in the in vivo assessment of the tissue com-\ncomplications of clinical devices derive from inadequate bio- patibility of medical devices. This chapter draws heavily on\ncompatibility. Moreover, the concept of biocompatibility has the ISO 10993 standard, Biological Evaluation of Medical", "compatibility. Moreover, the concept of biocompatibility has the ISO 10993 standard, Biological Evaluation of Medical\nevolved in recent years as biomaterials technology has become Devices, in presenting a systematic approach to the in vivo\nmore sophisticated, particularly in permitting the biomate- assessment of tissue compatibility of medical devices.\nrial to effect complex, and potentially beneficial, interactions The nature and extent of risk due to inadequate biocompat-", "rial to effect complex, and potentially beneficial, interactions The nature and extent of risk due to inadequate biocompat-\nwith the surrounding tissues (Hench and Pollak, 2002; Wil- ibility may be conceptualized as shown in Fig. 2.3.4.1. The first\nliams, 2008, 2019; see Chapter 2.3.2). Thus, the contempo- consideration in the selection of biomaterials to be used in device\nrary definition of biocompatibility focuses on the ability of a design should be the chemical, toxicological, physical, electrical,", "rary definition of biocompatibility focuses on the ability of a design should be the chemical, toxicological, physical, electrical,\nmedical device to perform with an appropriate host response morphological, and mechanical properties of the biomaterial(s)\nin a specific application, and biocompatibility assessment to fulfill the intended use. Relevant to the overall in vivo assess-\nserves as a measurement of the magnitude and duration of ment of tissue compatibility of a biomaterial or device is knowl-", "serves as a measurement of the magnitude and duration of ment of tissue compatibility of a biomaterial or device is knowl-\nthe pathophysiologic mechanisms that determine the host edge of the chemical composition of the materials, and the\nresponse. From a practical perspective, the in vivo assessment nature, degree, frequency, and duration of exposure of the device\nof tissue compatibility of medical devices is carried out to and its constituents to the tissues in which it will be utilized.", "of tissue compatibility of medical devices is carried out to and its constituents to the tissues in which it will be utilized.\ndetermine that the device performs as intended, and presents Table 2.3.4.1 presents a list of biomaterial components and\nno significant harm to the patient or user simulating clinical characteristics that may affect the overall biological responses of\nuse. In this chapter, the term “medical device” will be used to the medical device. The range of potential biological hazards is", "use. In this chapter, the term “medical device” will be used to the medical device. The range of potential biological hazards is\ndescribe biomaterials, prostheses, artificial organs, and other broad, and may include short-term effects, long-term effects, or\nmedical devices, and the terms “tissue compatibility assess- specific toxic effects, which should be considered for every mate-\nment,” “biocompatibility assessment,” and “safety assess- rial and medical device. However, this does not imply that test-", "ment,” “biocompatibility assessment,” and “safety assess- rial and medical device. However, this does not imply that test-\nment” will be considered to be synonymous. ing for all potential hazards will be necessary or practical.\nThe in vivo assessment of tissue compatibility is necessary to\nSelection of in Vivo Tests According to\nestablish the biocompatibility, safety, and function (efficacy)\nof a medical device and its components under conditions Intended Use\nof intended use. Intended use conditions are also utilized\nto select in vitro tests and animal models that will provide", "of intended use. Intended use conditions are also utilized\nto select in vitro tests and animal models that will provide\nAs it is recognized that biomaterial–tissue interaction may\nessential information to determine biocompatibility.\nvary with the anatomic site and duration of exposure, and\n869", "--- Page 2 ---\n870 SECTION 2.3 Characterization of Biomaterials\n• Figure 2.3.4.1 The risks associated with inadequate biocompatibility are a composite function of the\nexposure (i.e., nature and duration), the hazard (i.e., effects on the recipient), and the probability and con-\nsequences of complications.\nTABLE Biomaterials and Components Relevant to In TABLE Medical Device Categorization by Tissue\n2.3.4.1 Vivo Assessment of Tissue Compatibility 2.3.4.2 Contact and Contact Duration\nThe material(s) of manufacture Tissue Contact", "2.3.4.1 Vivo Assessment of Tissue Compatibility 2.3.4.2 Contact and Contact Duration\nThe material(s) of manufacture Tissue Contact\nIntended additives, process contaminants, and residues Surface devices Skin\nMucosal membranes\nLeachable substances\nBreached or compromised surfaces\nDegradation products\nExternal Blood path, indirect\nOther components and their interactions in the final communicating Tissue/bone/dentin communicating\nproduct devices Circulating blood\nThe properties and characteristics of the final product Implant devices Tissue/bone\nBlood\nContact Duration", "product devices Circulating blood\nThe properties and characteristics of the final product Implant devices Tissue/bone\nBlood\nContact Duration\napplication-specific conditions, in vivo tests for assess-\nLimited: ≤24 h\nProlonged: >24 h and <30 days\nment of tissue compatibility are chosen to simulate end-use\nPermanent: >30 days\napplications. To facilitate the selection of appropriate tests,\nmedical devices with their component biomaterials can be\ncategorized by the nature of tissue contact of the medical", "medical devices with their component biomaterials can be\ncategorized by the nature of tissue contact of the medical\ndevice, and by its duration of contact. Table 2.3.4.2 presents The first perspective involves the utilization of in vivo tests to\nmedical device categorization by nature of tissue contact and determine the general biocompatibility of newly developed\ncontact duration. The tissue contact categories and subcat- biomaterials for which some knowledge of the tissue compat-", "contact duration. The tissue contact categories and subcat- biomaterials for which some knowledge of the tissue compat-\negories, as well as the contact duration categories, have been ibility is necessary for further research and development. In\nderived from standards, protocols, and guidelines utilized this type of situation, manufacturing and other processes nec-\nin the past for safety evaluation of medical devices. Certain essary to the development of a final product, i.e., the medical", "in the past for safety evaluation of medical devices. Certain essary to the development of a final product, i.e., the medical\ndevices may fall into more than one category, in which case device, have not been carried out. However, the in vivo assess-\ntesting appropriate to each category should be considered. ment of tissue compatibility at this early stage of development\ncan provide additional information relating to the proposed\ndesign criteria in the production of a medical device. While it\nBiomaterial and Device Perspectives in In\nis generally recommended that the identification and quan-", "Biomaterial and Device Perspectives in In\nis generally recommended that the identification and quan-\nVivo Testing tification of extractable chemical entities of a medical device\nshould precede biological evaluation, it is quite common to\nTwo perspectives may be considered in the in vivo assessment carry out preliminary in vivo assessments to determine if there\nof tissue compatibility of biomaterials and medical devices. may be unknown or as-yet unidentified chemical entities that", "--- Page 3 ---\nCHAPTER 2.3.4 In Vivo Assessment of Tissue Compatibility 871\nchapter. ISO 10993 standards advise that the biological\nTABLE\nIn Vivo Tests for Tissue Compatibility\n2.3.4.3 evaluation of all medical device materials include testing for\ncytotoxicity, sensitization, and irritation. (Cytotoxicity tests\nSensitization\nare considered in vitro tests.) Beyond these fundamentals,\nIrritation the selection of further tests for in vivo biocompatibility\nassessment is based on the characteristics and end-use appli-\nIntracutaneous reactivity", "assessment is based on the characteristics and end-use appli-\nIntracutaneous reactivity\ncation of the device or biomaterial under consideration.\nSystemic toxicity (acute toxicity)\nSubchronic toxicity (subacute toxicity) Sensitization, Irritation, and Intracutaneous\nGenotoxicity (Intradermal) Reactivity\nImplantation\nExposure to, or contact with, even minute amounts of\nHemocompatibility potential leachables from medical devices or biomaterials\ncan result in allergic or sensitization reactions. Sensitization\nChronic toxicity\ntests estimate the potential for contact sensitization to medi-", "can result in allergic or sensitization reactions. Sensitization\nChronic toxicity\ntests estimate the potential for contact sensitization to medi-\nCarcinogenicity\ncal devices, materials, and/or their extracts. Symptoms of\nReproductive and developmental toxicity sensitization are often seen in skin, and tests are often car-\nried out topically in guinea pigs. Test design should reflect\nBiodegradation\nthe intended route (skin, eye, mucosa) and nature, degree,\nImmune responses\nfrequency, duration, and conditions of exposure of the bio-", "the intended route (skin, eye, mucosa) and nature, degree,\nImmune responses\nfrequency, duration, and conditions of exposure of the bio-\nmaterial in its intended clinical use. While sensitization reac-\ntions are immune system responses to contact with chemical\nproduce adverse biological reactions. Utilized in this fashion, substances, ISO guidelines suggest irritation to be a local tis-\nearly in vivo assessment of the tissue compatibility of a bio- sue inflammation response to chemicals, without a systemic", "early in vivo assessment of the tissue compatibility of a bio- sue inflammation response to chemicals, without a systemic\nmaterial may provide insight into the biocompatibility, and immunological component. The most severely irritating\nthereby may permit further development of this biomaterial chemical leachables may be discovered prior to in vivo studies\ninto a medical device. Obviously, problems observed at this by careful material characterization and in vitro cytotoxicity", "into a medical device. Obviously, problems observed at this by careful material characterization and in vitro cytotoxicity\nstage of development would require further efforts to improve tests. Irritant tests emphasize utilization of extracts of the bio-\nthe biocompatibility of the biomaterial, and to identify the materials to determine the irritant effects of potential leach-\nagents and mechanisms responsible for the adverse reactions. ables. Intracutaneous (intradermal) reactivity tests determine", "agents and mechanisms responsible for the adverse reactions. ables. Intracutaneous (intradermal) reactivity tests determine\nAs the in vivo assessment of tissue compatibility of a biomate- the localized reaction of tissue to intracutaneous injection of\nrial or medical device is focused on the end-use application, it extracts of medical devices, biomaterials, or prostheses in the\nmust be appreciated that a biomaterial considered compatible final product form. Intracutaneous tests may be applicable", "must be appreciated that a biomaterial considered compatible final product form. Intracutaneous tests may be applicable\nfor one application may not be compatible for another. where determination of irritation by dermal or mucosal tests\nThe second perspective regarding the in vivo assessment of is not appropriate. Albino rabbits are most commonly used,\ntissue compatibility of medical devices focuses on the biocom- however newer ISO guidelines refer to determination of skin", "tissue compatibility of medical devices focuses on the biocom- however newer ISO guidelines refer to determination of skin\npatibility of the final product, that is, the fabricated medical irritation using reconstructed human epidermis as an alter-\ndevice in the condition in which it is to be implanted. Thus, native to animal testing (ISO 10933-23).\nissues related to desired fabrications, interactions between bio- Since these tests focus on determining the biological\nmaterials, and to mechanical conductors, etc., may come into response of leachable constituents of biomaterials, their", "materials, and to mechanical conductors, etc., may come into response of leachable constituents of biomaterials, their\nplay. Although medical devices in their final form and condition extracts in various solvents are utilized to prepare the injec-\nare commonly implanted in carefully selected animal models to tion solutions. Critical to the conduct of these tests is that\ndetermine function, as well as biocompatibility, it may be inap- the preparation of the test material and/or extract solution", "determine function, as well as biocompatibility, it may be inap- the preparation of the test material and/or extract solution\npropriate to carry out all of the recommended tests necessary should be chosen to include testing for both water-soluble\nfor regulatory approval on the final device. In these situations, and fat-soluble leachables.\nsome tests may initially be carried out on biomaterial compo-\nnents of devices that have been prepared under manufacturing Systemic Toxicity: Acute, Subacute, and\nand sterilization conditions, and other processes utilized in the Subchronic Toxicity", "and sterilization conditions, and other processes utilized in the Subchronic Toxicity\nfinal product (see Table 2.3.4.3).\nSystemic toxicity tests estimate the potential harmful effects\nin vivo on target tissues and organs away from the point of\nSpecific Biological Properties Assessed by\ncontact (i.e., site of implantation) with either single or multiple\nIn Vivo Tests exposures to medical devices, biomaterials, and/or their extracts.\nThese tests evaluate the systemic toxicity potential of medical", "In Vivo Tests exposures to medical devices, biomaterials, and/or their extracts.\nThese tests evaluate the systemic toxicity potential of medical\nIn this section, brief perspectives on the general types of devices that release constituents into the body. These tests also\nin vivo tests are presented. Details regarding these tests are include pyrogenicity testing, which assesses the induction of a\nfound in the lists of standards provided at the end of this systemic inflammatory response, often measured as fever.", "--- Page 4 ---\n872 SECTION 2.3 Characterization of Biomaterials\nIn tests using extracts, the form and area of the mate- TABLE Biological Response Parameters as\nrial, the thickness, and the surface area to extraction vehicle 2.3.4.4 Determined by Histological Assessment of\nvolume are critical considerations in the testing protocol. Implants\nAppropriate extraction vehicles, i.e., solvents, should be cho-\nNumber and distribution of inflammatory cells as a function\nsen to yield a maximum extraction of leachable materials for\nof distance from the material/tissue interface", "sen to yield a maximum extraction of leachable materials for\nof distance from the material/tissue interface\nuse in the testing. Mice, rats, or rabbits are the usual animals\nof choice for the conduct of these tests, and oral, dermal, Thickness and vascularity of fibrous capsule\ninhalation, intravenous, intraperitoneal, or subcutaneous Quality and quantity of tissue ingrowth (for porous\napplication of the test substance may be used, depending on materials)\nthe intended application of the biomaterial. Acute toxicity is\nDegeneration as determined by changes in tissue", "the intended application of the biomaterial. Acute toxicity is\nDegeneration as determined by changes in tissue\nconsidered to be the adverse effects that occur after admin- morphology\nistration of a single dose or multiple doses of a test sample\nPresence of necrosis\ngiven within 24 h. Subacute toxicity (repeat dose toxicity)\nfocuses on adverse effects occurring after administration of Other parameters such as material debris, fatty infiltration,\ngranuloma, dystrophic calcification, apoptosis,\na single dose or multiple doses of a test sample per day dur-", "granuloma, dystrophic calcification, apoptosis,\na single dose or multiple doses of a test sample per day dur-\nproliferation rate, biodegradation, thrombus formation,\ning a period of from 14 to 28 days. Subchronic toxicity is\nendothelialization, migration of biomaterials or\nconsidered to be the adverse effects occurring after adminis- degradation products\ntration of a single dose or multiple doses of a test sample per\nday given during a part of the lifespan, usually 90 days but\nnot exceeding 10% of the lifespan of the animal.", "day given during a part of the lifespan, usually 90 days but\nnot exceeding 10% of the lifespan of the animal.\nPyrogenicity tests are also included in the system toxic- sample of a material or final product at the site where it\nity category to detect material-mediated fever-causing reac- is surgically implanted or placed into an implant site or\ntions to extracts of medical devices or material. Although tissue appropriate to the intended application of the bio-\nthe rabbit pyrogen test has been the standard, the Limulus material or medical device. In some cases, the anatomic", "the rabbit pyrogen test has been the standard, the Limulus material or medical device. In some cases, the anatomic\namebocyte lysate (LAL) reagent test has been used increas- site of implantation used for biocompatibility evaluation is\ningly in recent years and is considered an appropriate testing not the same as the site of ultimate use, but has representa-\nmethod. It is noteworthy that no single test can differentiate tive mechanisms and consequences of tissue–biomaterial\npyrogenic reactions that are material mediated per se from interaction (e.g., subcutaneous implantation in rodents", "pyrogenic reactions that are material mediated per se from interaction (e.g., subcutaneous implantation in rodents\nthose due to endotoxin contamination. of bioprosthetic heart valve materials to study calcifica-\ntion that occurs as a major clinical limitation in humans;\nsee Chapter 2.4.5). The most basic evaluation of the local\nGenotoxicity\npathological effects is carried out at both the gross level\nIn vivo genotoxicity tests are carried out if indicated by the and the microscopic level. Histological (microscopic) eval-", "In vivo genotoxicity tests are carried out if indicated by the and the microscopic level. Histological (microscopic) eval-\nchemistry and/or composition of the biomaterial (see Table uation is used to characterize various biological response\n2.3.4.1) or if in vitro test results indicate potential genotox- parameters (Table 2.3.4.4). To address specific questions,\nicity [changes in deoxyribonucleic acid (DNA) that could more sophisticated studies may need to be done. Exam-\nlead to changes in cellular proliferation, differentiation, and/ ples include immunohistochemical staining of histologi-", "lead to changes in cellular proliferation, differentiation, and/ ples include immunohistochemical staining of histologi-\nor function]. Initially, at least three in vitro assays should cal sections to determine the types of cells present, and\nbe used, and two of these assays should utilize mammalian studies of collagen formation and destruction. For short-\ncells. The initial in vitro assays should cover the three levels term implantation evaluation out to 12 weeks, mice, rats,\nof genotoxic effects: DNA destruction; gene mutations; and guinea pigs, or rabbits are the most common animals uti-", "of genotoxic effects: DNA destruction; gene mutations; and guinea pigs, or rabbits are the most common animals uti-\nchromosomal aberrations (as assessed by cytogenetic analy- lized in these studies. For longer-term testing in subcuta-\nsis). In vivo genotoxicity tests include the micronucleus neous tissue, muscle, or bone, animals such as rats, guinea\ntest and the in vivo mammalian bone marrow cytogenetic pigs, rabbits, dogs, sheep, goats, pigs, and other animals\ntests—chromosomal analysis, the rodent dominant lethal with relatively long life expectancies are suitable. If a com-", "tests—chromosomal analysis, the rodent dominant lethal with relatively long life expectancies are suitable. If a com-\ntests, the mammalian germ cell cytogenetic assay, the mouse plete medical device is to be evaluated, larger species may\nspot test, and the mouse heritable translocation assay. Not be utilized so that human-sized devices may be used in\nall of the in vivo genotoxicity tests need be performed; the the site of intended application. For example, substitute\nmost common test is the rodent micronucleus test. Geno- heart valves are usually tested as heart valve replacements", "most common test is the rodent micronucleus test. Geno- heart valves are usually tested as heart valve replacements\ntoxicity tests are performed with appropriate extracts or dis- in sheep, whereas calves are usually the animal of choice\nsolved materials using appropriate media, as suggested by for ventricular assist devices and total artificial hearts.\nthe known composition of the biomaterial. In all aspects of biocompatibility testing, it is impor-\ntant to recognize that the effects of the material on the sur-\nrounding tissues are generally superimposed on the events\nImplantation", "tant to recognize that the effects of the material on the sur-\nrounding tissues are generally superimposed on the events\nImplantation\noccurring during physiological wound repair induced by the\nImplantation tests assess the local pathological effects on surgery of implantation. This is particularly important in\nthe structure and function of living tissue induced by a shorter term experiments.", "--- Page 5 ---\nCHAPTER 2.3.4 In Vivo Assessment of Tissue Compatibility 873\nHemocompatibility single or multiple exposures or contacts over a period of the\nmajor portion of the lifespan of the test animal. Both carcino-\nHemocompatibility tests evaluate effects on blood and/or\ngenicity (tumorigenicity) and chronic toxicity may be studied\nblood components by blood-contacting medical devices\nin a single experimental study. With biomaterials, these studies\nor materials. In vivo hemocompatibility tests are usually\nfocus on the potential for solid-state carcinogenicity, i.e., the", "or materials. In vivo hemocompatibility tests are usually\nfocus on the potential for solid-state carcinogenicity, i.e., the\ndesigned to simulate the geometry, contact conditions, and\nOppenheimer effect (see Chapter 2.2.7). Thus, in carcinoge-\nflow dynamics of the device or material in its clinical applica-\nnicity testing, controls of a comparable form and shape should\ntion. From the ISO standards perspective, five test categories\nbe included; polyethylene implants are a commonly used con-\nare indicated for hemocompatibility evaluation: thrombosis;", "be included; polyethylene implants are a commonly used con-\nare indicated for hemocompatibility evaluation: thrombosis;\ntrol material. The use of appropriate controls is imperative as\ncoagulation; platelets; hematology; and immunology (com-\nanimals may spontaneously develop tumors, and statistical\nplement and leukocytes). Two levels of evaluation are indi-\ncomparison between the test biomaterial/device and the con-\ncated: Level 1 (required); and Level 2 (optional). Regardless\ntrols is necessary. To facilitate and reduce the time period for", "cated: Level 1 (required); and Level 2 (optional). Regardless\ntrols is necessary. To facilitate and reduce the time period for\nof blood contact duration, hemocompatibility testing is\ncarcinogenicity testing of biomaterials, the FDA is exploring\nindicated for three categories of medical devices: (1) external\nthe use of transgenic mice carrying the human prototype c-Ha-\ncommunicating devices—blood path indirect; (2) external\nras gene as a bioassay model for rapid carcinogenicity testing.\ncommunicating devices—circulating blood; and (3) blood-", "ras gene as a bioassay model for rapid carcinogenicity testing.\ncommunicating devices—circulating blood; and (3) blood-\nSince tumors associated with clinical medical devices\ncontacting implant devices. Chapter 2.3.5 gives further\nhave been rare (see Chapter 2.2.7) carcinogenicity tests\ndetails on the testing of blood–material interactions.\nshould be conducted only if data from other sources suggest\nSeveral issues are important in the selection of tests for\na tendency for tumor induction. However, considerations\nhemocompatibility of medical devices or biomaterials. In", "a tendency for tumor induction. However, considerations\nhemocompatibility of medical devices or biomaterials. In\nof carcinogenicity may become important in some future\nparticular, the hemocompatibility depends not only on the\napplications in which pluripotential stem cells produced by\nmaterial’s characteristics, but also on the fluid mechanics of\nany methodology are used.\nthe device (i.e., stasis promotes thrombus formation), and\nthe coagulability of the blood. Thus, in vivo testing in ani-\nReproductive and Developmental Toxicity\nmals may be convenient, but anatomic differences among", "Reproductive and Developmental Toxicity\nmals may be convenient, but anatomic differences among\nspecies and species-related differences in blood reactivity\nThese tests evaluate the potential effects of medical devices,\nmust be considered, and these may limit the predictability of\nmaterials, and/or their extracts on reproductive function,\nany given test in the human clinical situation. While blood\nembryonic development (teratogenicity), and prenatal\nvalues and reactivity between humans and nonhuman pri-\nand early postnatal development. The application site of", "values and reactivity between humans and nonhuman pri-\nand early postnatal development. The application site of\nmates are very similar, European Community law prohibits\nthe device must be considered, and tests and/or bioassays\nthe use of nonhuman primates for blood compatibility and\nshould only be conducted when the device has a potential\nmedical device testing. Hemocompatibility evaluation in\nimpact on the reproductive potential of the subject.\nanimals is complicated by the lack of appropriate and ade-\nquate test materials, for example, appropriate antibodies for\nBiodegradation", "animals is complicated by the lack of appropriate and ade-\nquate test materials, for example, appropriate antibodies for\nBiodegradation\nimmunoassays. Use of human blood in hemocompatibility\nevaluation implies in vitro testing, which usually requires the\nBiodegradation tests determine the effects of a biodegradable\nuse of anticoagulants that are not generally present with the\nmaterial and its biodegradation products on the tissue response.\ndevice in the clinical situation, except for perhaps the earli-\nThey focus on the amount of degradation during a given period", "device in the clinical situation, except for perhaps the earli-\nThey focus on the amount of degradation during a given period\nest implantation period. Although species differences may\nof time (the kinetics of biodegradation), the nature of the deg-\ncomplicate hemocompatibility evaluation, the utilization of\nradation products, the origin of the degradation products (e.g.,\nanimals in short- and long-term testing is considered to be\nimpurities, additives, corrosion products, bulk polymer), and\nappropriate for evaluating thrombosis and tissue interaction.", "impurities, additives, corrosion products, bulk polymer), and\nappropriate for evaluating thrombosis and tissue interaction.\nthe qualitative and quantitative assessment of degradation prod-\nucts and leachables in adjacent tissues and in distant organs.\nChronic Toxicity The biodegradation of biomaterials may occur through a wide\nvariety of mechanisms, which in part are biomaterial depen-\nChronic toxicity tests determine the effects of either single dent, and all pertinent mechanisms related to the device and", "Chronic toxicity tests determine the effects of either single dent, and all pertinent mechanisms related to the device and\nor multiple exposures to medical devices, materials, and/or the end-use application of the device must be considered. Test\ntheir extracts during a period of at least 10% of the lifes- materials comparable to degradation products may be prepared\npan of the test animal, e.g., over 90 days in rats. Chronic and studied to determine the biological response of degradation", "pan of the test animal, e.g., over 90 days in rats. Chronic and studied to determine the biological response of degradation\ntoxicity tests may be considered an extension of subchronic products anticipated in long-term implants. An example of this\n(subacute) toxicity testing, and both may be evaluated in an approach is the study of metallic and polymeric wear particles\nappropriate experimental protocol or study. that may be present with long-term orthopedic joint prosthe-\nses. Moreover, for intentionally biodegradable scaffolds used in", "ses. Moreover, for intentionally biodegradable scaffolds used in\nCarcinogenicity tissue engineering (see Chapter 2.6.3), biodegradation and the\nattendant tissue response are important to follow histologically.\nCarcinogenicity tests determine the tumorigenic potential of Further insights on biodegradation are available in Chapters\nmedical devices, materials, and/or their extracts from either 1.3.2F, 1.3.3D and Section 2.4.", "--- Page 6 ---\n874 SECTION 2.3 Characterization of Biomaterials\nImmune Responses tests for immunotoxicity in the future. Direct measures of\nimmune system activity by functional assays are the most\nImmune response evaluation is not a component of the\nimportant types of tests for immunotoxicity. Functional\nstandards currently available for in vivo tissue compatibil-\nassays are generally more important than tests for soluble\nity assessment. However, ASTM, ISO, and the FDA cur-\nmediators, which are more important than phenotyping.\nrently have working groups developing guidance documents", "mediators, which are more important than phenotyping.\nrently have working groups developing guidance documents\nSigns of illness may be important in in vivo experiments,\nfor immune response evaluation where pertinent. Synthetic\nmaterials are not generally immunotoxic (see Chapter 2.2.3).\nHowever, immune response evaluation is necessary with TABLE Potential Immunological Effects and\nmodified natural tissue implants such as collagen, which has 2.3.4.5 Responses\nbeen utilized in a number of different types of implants and\nEffects\nmay elicit immunological responses. The Center for Devices", "been utilized in a number of different types of implants and\nEffects\nmay elicit immunological responses. The Center for Devices\nand Radiological Health of the FDA released a draft immu- Hypersensitivity\nnotoxicity testing guidance document in 1998 (Langone, Type I—anaphylactic\n1998), whose purpose is to provide a systematic approach\nType II—cytotoxic\nfor evaluating potential adverse immunological effects of\nmedical devices and constituent materials. However, there Type III—immune complex\nhave only been updated documents on pharmaceuticals and Type IV—cell-mediated (delayed)", "have only been updated documents on pharmaceuticals and Type IV—cell-mediated (delayed)\nnot medical devices (S8 Immunotoxicity Studies for Human\nChronic inflammation\nPharmaceuticals, 2005). Immunotoxicity is any adverse\neffect on the function or structure of the immune system or Immunosuppression\nother systems as a result of an immune system dysfunction. Immunostimulation\nAdverse or immunotoxic effects occur when humoral or cel-\nAutoimmunity\nlular immunity needed by the host to defend itself against\ninfections or neoplastic disease (immunosuppression) or Responses", "Autoimmunity\nlular immunity needed by the host to defend itself against\ninfections or neoplastic disease (immunosuppression) or Responses\nunnecessary tissue damage (chronic inflammation, hypersen- Histopathological changes\nsitivity, or autoimmunity) is compromised. Potential immu-\nHumoral responses\nnological effects and responses that may be associated with\none or more of these effects are presented in Table 2.3.4.5. Host resistance\nRepresentative tests for the evaluation of immune\nClinical symptoms\nresponses are given in Table 2.3.4.6. Table 2.3.4.6 is not\nCellular responses", "Representative tests for the evaluation of immune\nClinical symptoms\nresponses are given in Table 2.3.4.6. Table 2.3.4.6 is not\nCellular responses\nall-inclusive, and other tests that specifically consider pos-\nsible immunotoxic effects potentially generated by a given T cells\ndevice or its components may be applicable. Examples pre-\nNatural killer cells\nsented in Table 2.3.4.6 are only representative of the large\nMacrophages\nnumber of tests that are currently available. However, direct\nand indirect markers of immune responses may be validated Granulocytes", "Macrophages\nnumber of tests that are currently available. However, direct\nand indirect markers of immune responses may be validated Granulocytes\nand their predictive value documented, thus providing new\nTABLE\nRepresentative Tests for the Evaluation of Immune Responses\n2.3.4.6\nFunctional Assays Phenotyping Soluble Mediators Signs of Illness\nSkin testing Cell surface markers Antibodies Allergy\nImmunoassays (e.g., ELISA) MHC markers Complement Skin rash\nLymphocyte proliferation Chemokines Immune complexes Urticaria\nPlaque-forming cells Basoactive amines Cytokine patterns(T-cell subsets) Edema", "Lymphocyte proliferation Chemokines Immune complexes Urticaria\nPlaque-forming cells Basoactive amines Cytokine patterns(T-cell subsets) Edema\nLocal lymph node assay – Cytokines (IL-1, IL-1ra, TNFα, IL-6, Lymphadenopathy\nTGF-β, IL-4, IL-13)\nMixed lymphocyte reaction – – –\nTumor cytotoxicity – – –\nAntigen presentation – – –\nPhagocytosis – – –", "--- Page 7 ---\nCHAPTER 2.3.4 In Vivo Assessment of Tissue Compatibility 875\nbut symptoms may also have a significant role in studies of A single test animal may not assess all pertinent clinically\nimmune function in clinical trials and postmarket studies. important complications. For example, as described earlier,\nCombination devices where drugs (or cells) are uti- sheep are commonly used for the evaluation of heart valves\nlized within medical devices should also be considered (see Chapter 2.5.2A). This is based on size considerations,", "lized within medical devices should also be considered (see Chapter 2.5.2A). This is based on size considerations,\nfor immune response evaluation. Hypersensitivity reac- and also the propensity to calcify tissue components of bio-\ntions have been reported with drug-eluting coronary stents prosthetic heart valves and thereby be a sensitive model for\n(DES). With DES, concomitantly prescribed medications this complication. Thus, the choice of this animal model\nsuch as clopidogrel (platelet inhibitor) have been considered for bioprosthetic heart valve evaluation is made on the basis", "such as clopidogrel (platelet inhibitor) have been considered for bioprosthetic heart valve evaluation is made on the basis\nthe causative agent for hypersensitivity, as well as the DES of accelerated calcification, the major clinical problem,\nitself (Nebeker et al., 2006). assessed in rapidly growing animals which has its clinical\ncorrelation in young and adolescent humans. Nevertheless,\nSelection of Animal Models for In Vivo Tests normal sheep may not provide a sensitive assessment of the\npropensity of a valve to thrombosis, which may be poten-", "propensity of a valve to thrombosis, which may be poten-\nAnimal models are used to predict the clinical behavior, tiated by the reduced flow seen in abnormal subjects, but\nsafety, and biocompatibility of medical devices in humans diminished by the specific coagulation profile of sheep.\n(Table 2.3.4.7). The selection of animal models for the The in vivo assessment of tissue responses to vascular graft\nin vivo assessment of tissue compatibility must consider materials is an example in which animal models present a", "in vivo assessment of tissue compatibility must consider materials is an example in which animal models present a\nthe advantages and disadvantages of the animal model for particularly misleading picture of what generally occurs in\nhuman clinical application. Several examples follow, which humans. Virtually all animal models, including nonhuman\nexemplify the advantages and disadvantages of animal mod- primates, heal rapidly and completely with an endothelial\nels in predicting clinical behavior in humans. blood-contacting surface. Humans, on the other hand,", "els in predicting clinical behavior in humans. blood-contacting surface. Humans, on the other hand,\ndo not show extensive endothelialization of vascular graft\nPreclinical testing in animal models is an important part of materials, and the resultant pseudointima from the healing\nthe regulatory process, used to determine the safety and\nresponse in humans has potential thrombogenicity. Conse-\nefficacy of devices prior to human clinical trials. The choice of\nquently, despite favorable results in animals, small-diameter\nthe animal model and the selection of in vitro tests should be", "quently, despite favorable results in animals, small-diameter\nthe animal model and the selection of in vitro tests should be\nmade according to the intended use of the respective medical vascular grafts (less than 4 mm in internal diameter) usually\ndevice, prosthesis, or biomaterial. yield early thrombosis in humans, the major mechanism of\nfailure which is secondary to the lack of endothelialization\nin the luminal surface-healing response.\nOriginally, the porcine coronary artery model was con-\nTABLE Animal Models for the In Vivo Assessment of", "in the luminal surface-healing response.\nOriginally, the porcine coronary artery model was con-\nTABLE Animal Models for the In Vivo Assessment of\nsidered the model of choice for the evaluation of arterial\n2.3.4.7 Medical Devices\nstents. More recently, the rabbit iliac artery model for the\nDevice Classification Animal evaluation of drug-eluting stents has been considered to be\nCardiovascular more realistic, as endothelialization is slower in the rabbit\nmodel than in the porcine model, and inflammation is not\nHeart valves Sheep", "model than in the porcine model, and inflammation is not\nHeart valves Sheep\nVascular grafts Dog, pig as extensive in the rabbit (Nakazawa et al., 2008). Thus,\nStents Pig, rabbit, dog endothelialization, healing, and inflammation in the rab-\nVentricular assist devices Calf bit iliac artery model may be closer to these responses in\nArtificial hearts Calf\nhumans than the porcine coronary artery model.\nEx vivo shunts Baboon, dog\nThe use of appropriate animal models is an important\nOrthopedic/Bone consideration in the safety evaluation of medical devices", "The use of appropriate animal models is an important\nOrthopedic/Bone consideration in the safety evaluation of medical devices\nBone regeneration/ Rabbit, dog, pig, mouse, rat that may contain potential immunoreactive materials. The\nSubstitutes Dog, goat, nonhuman primate in vivo evaluation of recombinant human growth hormone\nTotal joints—hips, knees Sheep, goat, baboon\nin poly(lactic-co-glycolic acid) (PLGA) microspheres dem-\nVertebral implants Rabbit, pig, dog, nonhuman\nonstrates the appropriate use of various animal models to\nprimate", "Vertebral implants Rabbit, pig, dog, nonhuman\nonstrates the appropriate use of various animal models to\nprimate\nCraniofacial implants Rabbit, dog evaluate biological responses and the potential for immu-\nCartilage Dog, sheep notoxicity. Utilizing biodegradable PLGA microspheres\nTendon and ligament Goat containing recombinant human growth hormone (rhGH,\nsubstitutes\nCleland et al., 1997) used Rhesus monkeys, transgenic mice\nNeurological expressing hGH, and normal control (Balb/C) mice in their\nPeripheral nerve Rat, cat, nonhuman primate in vivo evaluation studies. Rhesus monkeys were utilized", "Peripheral nerve Rat, cat, nonhuman primate in vivo evaluation studies. Rhesus monkeys were utilized\nregeneration for serum assays in the pharmacokinetic studies of rhGH\nElectrical stimulation Rat, cat, nonhuman primate\nrelease, as well as tissue responses to the injected microcap-\nOphthalmological sule formulation. Placebo injection sites were also utilized,\nContact lens Rabbit and a comparison of the injection sites from rhGH PLGA\nIntraocular lens Rabbit, monkey microspheres and placebo PLGA microspheres demon-\nstrated a normal inflammatory and wound-healing response", "--- Page 8 ---\n876 SECTION 2.3 Characterization of Biomaterials\nwith a normal focal foreign-body reaction. To further in combinations with synthetic, i.e., passive, materials to\nexamine the tissue response, transgenic mice were utilized produce devices that control or modulate a desired tissue\nto assess the immunogenicity of the rhGH PLGA formu- response. Obviously, in vivo assessment of the targeted bio-\nlation. Transgenic mice expressing a heterologous protein logical response of a tissue-engineered device will play a sig-", "lation. Transgenic mice expressing a heterologous protein logical response of a tissue-engineered device will play a sig-\nhave been previously used for assessing the immunogenicity nificant role in the research and development of that device,\nof structural mutant proteins. With the transgenic animals, as well as in its safety assessment. It is clear that scientists\nno detectable antibody response to rhGH was found. In working on the development of tissue-engineered devices\ncontrast, the Balb/C control mice had a rapid onset of high- will contribute significantly to the development of in vivo", "contrast, the Balb/C control mice had a rapid onset of high- will contribute significantly to the development of in vivo\ntiter antibody response to the rhGH PLGA formulation. tests for biocompatibility assessment, as these tests will also\nThis study points out the appropriate utilization of animal be utilized to study the targeted biological responses in the\nmodels to not only evaluate biological responses, but also research phase of the device development.\none type of immunotoxicity (immunogenicity). Regarding tissue-engineered devices, it must be appreci-", "one type of immunotoxicity (immunogenicity). Regarding tissue-engineered devices, it must be appreci-\nated that biological components may induce varied effects\non tissue in the in vivo setting. For example, a simplistic\nFuture Perspectives on In Vivo Medical\nview of the potentially complex problems that might result\nDevice Testing from a device releasing a growth factor to enhance cell\nproliferation is presented. The presence of a growth factor\nAs presented earlier in this chapter, the in vivo assessment may result in markedly different cell proliferation, differ-", "As presented earlier in this chapter, the in vivo assessment may result in markedly different cell proliferation, differ-\nof tissue compatibility of biomaterials and medical devices entiation, protein synthesis, attachment, migration, shape\nis dependent on the end-use application of the biomaterial change, etc., which would be cell-type dependent. Thus,\nor medical device. In this sense, the development and uti- different cell-type dependent responses in an implant site,\nlization of new biomaterials and medical devices will dic- reacting to the presence of a single exogenous growth factor,", "lization of new biomaterials and medical devices will dic- reacting to the presence of a single exogenous growth factor,\ntate the development of new test protocols and procedures may result in inappropriate, inadequate, or adverse tissue\nfor evaluating these new products. Furthermore, it must be responses. These perspectives must be integrated into the\nunderstood that the in vivo assessment of tissue compatibil- planned program for in vivo assessment of tissue compat-\nity of biomaterials and medical devices is open ended, and ibility of tissue-engineered devices. Moreover, a major chal-", "ity of biomaterials and medical devices is open ended, and ibility of tissue-engineered devices. Moreover, a major chal-\nnew end-use applications will require new tests. lenge to the in vivo assessment of tissue compatibility of\ntissue-engineered devices is the use of animal tissue com-\nThe future development of medical devices is anticipated ponents in the early phase of device development, whereas\nto provide more complexity to the composition and\nthe ultimate goal is the utilization of human tissue compo-\nconstruction of these devices and, thus, to the array of", "the ultimate goal is the utilization of human tissue compo-\nconstruction of these devices and, thus, to the array of\nnents in the final device for end-use application. Novel and\npotential biomaterial–tissue interactions. Future assessments\nwill require a more sophisticated approach to test protocols innovative approaches to the in vivo tissue compatibility\nand methodologies that must clearly identify biocompatibility of tissue-engineered devices must be developed to address", "and methodologies that must clearly identify biocompatibility of tissue-engineered devices must be developed to address\nand function. In this regard, new tests, methods, and animal these significant issues. Finally, the development of clini-\nmodels may have to be developed to adequately and\ncally useful tissue-engineered devices will require enhanced\nappropriately characterize the biocompatibility and function of\nunderstanding of the influence of the patient and biome-\nthese new devices. Therefore, the development of guidelines", "understanding of the influence of the patient and biome-\nthese new devices. Therefore, the development of guidelines\nand standards is dynamic and constantly evolving, driven by chanical factors on the structure and function of healed and\nthe complexity of new devices developed for application in remodeled tissues. It will also require new methodology for\ntissue engineering, regenerative medicine, and nanomedicine. assessment of biocompatibility, and the dynamic progres-\nsion of remodeling in vivo (Mendelson and Schoen, 2006).", "sion of remodeling in vivo (Mendelson and Schoen, 2006).\nOver the past half-century, medical devices and bioma- Careful studies of retrieved implants to establish bio-\nterials have generally been “passive” in their tissue interac- markers and mechanisms of structural evolution will be\ntions. That is, a mechanistic approach to biomaterial–tissue critical (see Chapter 2.1.5).\ninteractions has rarely been used in the development of\nbiomaterials or medical devices. Heparinized biomaterials References\nare an exception to this, but considering the five subcatego-", "biomaterials or medical devices. Heparinized biomaterials References\nare an exception to this, but considering the five subcatego-\nries of hemocompatibility, these approaches have a minimal An, Y.H., Friedman, R.J., 1999. Animal Models in Orthopaedic\nimpact on the development of blood-compatible materials. Research. CRC Press, Boca Raton, FL.\nIn the past decade, increased emphasis has been placed Association for the Advancement of Medical Instrumentation, 1998.\non bioactivity and tissue engineering in the development AAMI standards and recommended practices, vol. 4. Biol. Eval.", "on bioactivity and tissue engineering in the development AAMI standards and recommended practices, vol. 4. Biol. Eval.\nMed. Dev. 4S (Suppl.) 1997.\nof biomaterials and medical devices for potential clini-\nChapekar, M.S., 1996. Regulatory concerns in the development of\ncal application. Rather than a “passive” approach to tissue\nbiologic–biomaterial combinations. J. Biomed. Mater. Res. Appl.\ninteractions, bioactive and tissue-engineered devices have\nBiomat. 33, 199–203.\nfocused on an “active” approach in which biological or\nCleland, J.L., Duenas, E., Daugherty, A., Marian, M., Yang, J., et al.,", "Biomat. 33, 199–203.\nfocused on an “active” approach in which biological or\nCleland, J.L., Duenas, E., Daugherty, A., Marian, M., Yang, J., et al.,\ntissue components, i.e., growth factors, cytokines, drugs,\n1997. Recombinant human growth hormone poly(lactic-co-gly-\nenzymes, proteins, extracellular matrix components, and colic acid) (PLGA) microspheres provide a long lasting effect. J.\ncells that may or may not be genetically modified, are used Control. Release 49, 193–205.", "--- Page 9 ---\nCHAPTER 2.3.4 In Vivo Assessment of Tissue Compatibility 877\nFDA (US Food and Drug Administration), 1995. Blue Book Memo- ISO-10993-23, Determination of Skin Irritation of Medical Device\nrandum G95–1: FDA-Modified Version of ISO 10993-Part 1, Extracts Using Reconstructed Human Epidermis (RhE).\nBiological Evaluation of Medical Devices – Part 1. Evaluation and ISO 14971, Medical Devices – Application of Risk Management to\nTesting. Medical Devices.\nHench, L.L., Pollak, J.M., 2002. Third-generation biomedical materi-\nals. Biomaterials 295, 1014–1017.", "Testing. Medical Devices.\nHench, L.L., Pollak, J.M., 2002. Third-generation biomedical materi-\nals. Biomaterials 295, 1014–1017.\nLangone, J.J., 1998. Immunotoxicity Testing Guidance. Draft Docu-\nASTM International, 2018 Annual Book of\nment, Office of Science and Technology. Center for Devices and\nRadiological Health, Food and Drug Administration. ASTM Standards, Volume 13.01\nMendelson, K., Schoen, F.J., 2006. Heart valve tissue engineering:\nconcepts, approaches, progress, and challenges. Ann. Biomed. F 895, Agar Diffusion Cell Culture Screening for Cytotoxicity.", "concepts, approaches, progress, and challenges. Ann. Biomed. F 895, Agar Diffusion Cell Culture Screening for Cytotoxicity.\nEng. 34, 1799–1819. F 2382, Assessment of Intravascular Medical Device Materials on\nNakazawa, G., Finn, A.V., Ladich, E., Ribichini, F., Coleman, L., Partial Thromboplastin Time (PTT).\net al., 2008. Drug-eluting stent safety: findings from preclinical E 1397, In Vitro Rat Hepatocyte DNA Repair Assay.\nstudies. Expert Rev. Cardiovasc. Ther. 6 (10), 1379–1391. E 1398 In Vivo Rat Hepatocyte DNA Repair Assay.", "studies. Expert Rev. Cardiovasc. Ther. 6 (10), 1379–1391. E 1398 In Vivo Rat Hepatocyte DNA Repair Assay.\nNebeker, J.R., Virmani, R., Bennett, C.L., Hoffman, J.M., F 1983, Assessment of Compatibility of Absorbable/Resorbable\nSamore, M.H., et al., 2006. Hypersensitivity cases associated Biomaterials for Implant Applications.\nwith drug-eluting coronary stents. J. Am. Coll. Cardiol. 47, F 981, Assessment of Compatibility of Biomaterials for Surgical\n175–181. Implants with Respect to Effect of Materials on Muscle and Bone.", "175–181. Implants with Respect to Effect of Materials on Muscle and Bone.\nWilliams, D.F., 2008. On the mechanisms of biocompatibility. Bio- F 756, Assessment of Hemolytic Properties of Materials.\nmaterials 29, 2941–2953. F 1027, Assessment of Tissue and Cell Compatibility of Orofacial\nWilliams, D.F., 2019. The language of biomaterials-based technolo- Prosthetic Materials and Devices.\ngies. Regen. Eng. Transl. Med. 5, 53–60. F 1877, Characterization of Particles.\nYamamoto, S., Urano, K., Koizumi, H., Wakana, S., Hioki, K., et al., F 813, Direct Contact Cell Culture Evaluation of Materials for", "Yamamoto, S., Urano, K., Koizumi, H., Wakana, S., Hioki, K., et al., F 813, Direct Contact Cell Culture Evaluation of Materials for\n1998. Validation of transgenic mice carrying the human prototype Medical Devices.\nc-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. F 749, Evaluating Material Extracts by Intracutaneous Injection in\nEnviron. Health Perspect. 106 (Suppl. 1), 57–69. the Rabbit.\nF 750, Evaluating Material Extracts by Systemic Injection in the Rabbit.\nF 2148, Evaluation of Delayed Contact Hypersensitivity Using the\nISO Standards", "F 2148, Evaluation of Delayed Contact Hypersensitivity Using the\nISO Standards\nMurine Local Lymph Node Assay (LLNA).\nF 1906, Evaluation of Immune Responses in Biocompatibility\nISO 10993, Biological Evaluation of Medical Devices. International Testing Using ELISA Tests, Lymphocyte Proliferation, and Cell\nStandards Organization, Geneva, Switzerland. Migration.\nISO 10993-1 Evaluation and Testing within a Risk Management F 619, Extraction of Medical Plastics.\nSystem. (2018). F 2147, Guinea Pig: Split Adjuvant and Closed Patch Testing for", "System. (2018). F 2147, Guinea Pig: Split Adjuvant and Closed Patch Testing for\nISO 10993-2, Animal Welfare Requirements. Contact Allergens.\nISO 10993-3, Tests for Genotoxicity, Carcinogenicity, and F 748, Selecting Generic Biological Test Methods for Materials and\nReproductive Toxicity. Devices.\nISO 10993-4, Selection of Tests for Interactions with Blood. F 1905, Selecting Tests for Determining the Propensity of Materials\nISO 10993-5, Tests for in Vitro Cytotoxicity. to Cause Immunotoxicity.", "ISO 10993-5, Tests for in Vitro Cytotoxicity. to Cause Immunotoxicity.\nISO 10993-6, Tests for Local Effects after Implantation. F 763, Short-Term Screening of Implant Materials.\nISO 10993-7, Ethylene Oxide Sterilization Residuals. F 1408, Subcutaneous Screening Test for Implant Materials.\nISO 10993-9, Framework for the Identification and Quantification of F 719, Testing Biomaterials in Rabbits for Primary Skin Irritation.\nPotential Degradation Products. F 1903, Testing for Biological Responses to Particles In Vitro.", "Potential Degradation Products. F 1903, Testing for Biological Responses to Particles In Vitro.\nISO 10993-10, Tests for Irritation and Delayed-type Hypersensitivity. F 720, Testing Guinea Pigs for Contact Allergens: Guinea Pig\nISO 10993-11, Tests for Systemic Toxicity. Maximization Test.\nISO 10993-12, Sample Preparation and Reference Materials. F 2065, Testing for Alternative Pathway Complement Activation in\nISO 10993-13, Identification and Quantification of Degradation Serum by Solid Materials.", "ISO 10993-13, Identification and Quantification of Degradation Serum by Solid Materials.\nProducts from Polymeric Medical Devices. F 2567, Testing for Classical Pathway Complement Activation in\nISO 10993-14, Identification and Quantification of Degradation Serum by Solid Materials.\nProducts from Ceramics. F 1984, Testing for Whole Complement Activation in Serum by Solid\nISO 10993-15, Identification and Quantification of Degradation Materials.\nProducts from Metals and Alloys. F 1904, Testing the Biological Responses to Particles In Vivo.", "Products from Metals and Alloys. F 1904, Testing the Biological Responses to Particles In Vivo.\nISO 10993-16, Toxicokinetic Study Design for Degradation Products E 1263, Conduct of Micronucleus Assays in Mammalian Bone\nand Leachables. Marrow Erythrocytes.\nISO 10993-17, Method for the Establishment of Allowable Limits for E 1202, Development of Micronucleus Assay Standards.\nLeachable Substances. E 1262, Performance of Chinese Hamster Ovary Cell/Hypoxanthine\nISO 10993-18, Chemical Characterization of Materials. Guanine Phosphoribosyl Transferase Gene Mutation Assay.", "ISO 10993-18, Chemical Characterization of Materials. Guanine Phosphoribosyl Transferase Gene Mutation Assay.\nISO 10993-19, Physico-Chemical Morphological and Topographical F 1439, Performance of Lifetime Bioassay for the Tumorigenic\nCharacterization of Materials. Potential of Implant Materials.\nISO-10993-20, Principles and Methods for Immunotoxicology E 1280, Performing the Mouse Lymphoma Assay for Mammalian\nTesting of Medical Devices. Cell Mutagenicity."]